The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
In vivo genome editing using Staphylococcus aureus Cas9
Open accessAbstract
The RNA-guided endonuclease Cas9 has emerged as a versatile genome-editing platform. However, the size of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its utility for basic research and therapeutic applications that use the highly versatile adeno-associated virus (AAV) delivery vehicle. Here, we characterize six smaller Cas9 orthologues and show that Cas9 from Staphylococcus aureus (SaCas9) can edit the genome with efficiencies similar to those of SpCas9, while being more than 1 kilobase shorter. We packaged SaCas9 and its single guide RNA expression cassette into a single AAV vector and targeted the cholesterol regulatory gene Pcsk9 in the mouse liver. Within one week of injection, we observed >40% gene modification, accompanied by significant reductions in serum Pcsk9 and total cholesterol levels. We further assess the genome-wide targeting specificity of SaCas9 and SpCas9 using BLESS, and demonstrate that SaCas9-mediated in vivo genome editing has the potential to be efficient and specific.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, the requirement of a specific PAM Sequence for targeted genome editing is crucial, and even though it reduces off-target activity, it often results in suboptimal DNA cleavage, editing efficiencies (Ran et al., 2015; Edraki et al., 2019) and restricting the scope of targeted edition.”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cas9 genomic localization is delimited by the protospacer adjacent motif (PAM), which is NGG for SpCas9 while evolved variants of SpCas9 tolerate a broader range of PAM sequences17–21.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The SpCas9 homolog derived from Staphylococcus aureus (SaCas9) has been extensively characterized as a highly efficient and significantly smaller alternative to SpCas9.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“It recognizes an NNGRRT PAM (where R = A or G)20.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Recent advancements in gene-editing technologies have led to the development of artificial Cas9 variants with relaxed PAM specificities, which improve efficiency but are associated with an increase in off-target effects and a decrease in target specificity (Ran et al., 2015).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measured
In the citing paper
“Recently, a smaller form of Cas9 was developed, and shown capable of packing and delivery with sgRNA by AAV in vivo12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“Adenovirus or adeno-associated virus (AAV)-mediated CRISPR-Cas9 delivery has been successfully applied to knockout genes in the mouse brain and liver12,13.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“A smaller form of Cas9 (Staphylococcus aureus Cas9), which fits into AAV vectors, has been recently used to knockout genes by NHEJ in the mouse liver. More than 40% indel formations in Pcsk9 locus was reported12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“For example, less than 10% indels at the Apob locus in the mouse liver was reported in the same study12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“However, the large genetic size of Cas9 (~ 4.5 kb) and the total plasmid size (> 7 kb) significantly increase the difficulty of delivery and expression of CRISPR/Cas9 systems [94].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“Although the newly discovered Cas9 form from Staphylococcus aureus strain (SaCas9) is about 1 kb shorter than SpCas9, the overall genetic size is still too large for application [94, 140].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“The Cas9 from Staphylococcus aureus (SaCas9) is over 1 kb shorter (3.15 kb) than SpCas9 [69].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationMfold web server for nucleic acid folding and hybridization prediction
Zuker, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg595 · Cited by 13,404
WebLogo: A Sequence Logo Generator: Figure 1Preprint
Crooks, G. E., Hon, G. C., Chandonia, J., & Brenner, S. E. (2004) · Genome Research · doi:10.1101/gr.849004 · Cited by 12,480
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Cited by
Sorted by citations
Items 401–500 of 1,009
Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery
Bolukbasi, M. F., Gupta, A., & Wolfe, S. A. (2015) · Nature Methods · doi:10.1038/nmeth.3684 · Cited by 112
CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases
Khan, F. A., Pandupuspitasari, N. S., Huang, C., Ao, Z., Jamal, M., Zohaib, A., Khan, F. A., Hakim, M. R., & ShuJun, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.9646 · Cited by 115
Programmable Extracellular Vesicles for Macromolecule Delivery and Genome Modifications
Zhang, X., Xu, Q., Zi, Z., Liu, Z., Wan, C., Crisman, L., Shen, J., & Liu, X. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.11.007 · Cited by 119
Sherkatghanad, Z., Abdar, M., Charlier, J., & Makarenkov, V. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad131 · Cited by 123
Genome Editing in Human Pluripotent Stem Cells: Approaches, Pitfalls, and Solutions
Hendriks, W. T., Warren, C. R., & Cowan, C. A. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2015.12.002 · Cited by 110
CRISPR guide RNA design for research applications
Mohr, S. E., Hu, Y., Ewen‐Campen, B., Housden, B. E., Viswanatha, R., & Perrimon, N. (2016) · FEBS Journal · doi:10.1111/febs.13777 · Cited by 112
Editing the genome of hiPSC with CRISPR/Cas9: disease models
Bassett, A. R. (2017) · Mammalian Genome · doi:10.1007/s00335-017-9684-9 · Cited by 125
The CRISPR /Cas revolution reaches the RNA world: Cas13, a new Swiss Army knife for plant biologists
Wolter, F., & Puchta, H. (2018) · The Plant Journal · doi:10.1111/tpj.13899 · Cited by 113
Short DNA Hairpins Compromise Recombinant Adeno-Associated Virus Genome Homogeneity
Xie, J., Mao, Q., Tai, P. W. L., He, R., Ai, J., Su, Q., Zhu, Y., Ma, H., Li, J., Gong, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.028 · Cited by 102
Non-viral delivery of genome-editing nucleases for gene therapy
Wang, M., Glass, Z., & Xu, Q. (2016) · Gene Therapy · doi:10.1038/gt.2016.72 · Cited by 113
A Robust CRISPR Interference Gene Repression System in Pseudomonas
Tan, S. Z., Reisch, C. R., & Prather, K. L. J. (2018) · Journal of Bacteriology · doi:10.1128/jb.00575-17 · Cited by 106
Alehashemi, S., & Goldbach‐Mansky, R. T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01840 · Cited by 108
Ibraheim, R., Tai, P. W. L., Mir, A., Javeed, N., Wang, J., Rodríguez, T., Namkung, S., Nelson, S. J., Khokhar, E. S., Mintzer, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26518-y · Cited by 112
An evolved AAV variant enables efficient genetic engineering of murine T cells
Nyberg, W. A., Ark, J., To, A., Clouden, S., Reeder, G. C., Muldoon, J. J., Chung, J.-Y., Xie, W. H., Allain, V., Steinhart, Z., et al. (2023) · Cell · doi:10.1016/j.cell.2022.12.022 · Cited by 113
The Bacterial Origins of the CRISPR Genome-Editing Revolution
Sontheimer, E. J., & Barrangou, R. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.091 · Cited by 113
Cardi, T. (2016) · Plant Breeding · doi:10.1111/pbr.12345 · Cited by 111
CRISPR/Cas9‑mediated cervical cancer treatment targeting human papillomavirus E6
Yoshiba, T., Saga, Y., Urabe, M., Uchibor, R., Matsubara, S., Fujiwara, H., & Mizukami, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.9815 · Cited by 112
Tools for efficient genome editing; ZFN, TALEN, and CRISPR
Shamshirgaran, Y., Liu, J., Sumer, H., Verma, P. J., & Taheri-Ghahfarokhi, A. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2301-5_2 · Cited by 114
Biodegradable Amino-Ester Nanomaterials for Cas9 mRNA Delivery in Vitro and in Vivo
Zhang, X., Li, B., Luo, X., Zhao, W., Jiang, J., Zhang, C., Gao, M., Chen, X., & Dong, Y. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b08163 · Cited by 107
Rationally engineered Staphylococcus aureus Cas9 nucleases with high genome-wide specificity
Tan, Y., Chu, A. H. Y., Bao, S., Hoang, D. A., Kebede, F. T., Xiong, W., Ji, M., Shi, J., & Zheng, Z. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906843116 · Cited by 110
PCSK9 and cancer: Rethinking the link
Mahboobnia, K., Pirro, M., Marini, E., Grignani, F., Bezsonov, E. E., Jamialahmadi, T., & Sahebkar, A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111758 · Cited by 112
Tools for experimental and computational analyses of off-target editing by programmable nucleases
Bao, X. R., Pan, Y., Lee, C. M., Davis, T. H., & Bao, G. (2021) · Nature Protocols · doi:10.1038/s41596-020-00431-y · Cited by 106
dCas9: A Versatile Tool for Epigenome Editing
Brocken, D. J. W., Tark‐Dame, M., & Dame, R. T. (2017) · Current Issues in Molecular Biology · doi:10.21775/cimb.026.015 · Cited by 113
She, K., Liu, Y., Zhao, Q., Jin, X., Yang, Y., Su, J., Li, R., Song, L., Xiao, J., Yao, S., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01234-1 · Cited by 106
Ligand-binding domains of nuclear receptors facilitate tight control of split CRISPR activity
Nguyen, D., Miyaoka, Y., Gilbert, L. A., Mayerl, S. J., Lee, B. H., Weissman, J. S., Conklin, B. R., & Wells, J. A. (2016) · Nature Communications · doi:10.1038/ncomms12009 · Cited by 107
Programmable Genome Editing Tools and their Regulation for Efficient Genome Engineering
Guha, T. K., Wai, A., & Hausner, G. (2017) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.12.006 · Cited by 117
Canver, M. C., Lessard, S., Pinello, L., Wu, Y., Ilboudo, Y., Stern, E. N., Needleman, A. J., Galactéros, F., Brugnara, C., Kutlar, A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3793 · Cited by 105
Wang, G., Chow, R. D.-W., Ye, L., Guzman, C. D., Dai, X., Dong, M. B., Zhang, F., Sharp, P. A., Platt, R. J., & Chen, S. (2018) · Science Advances · doi:10.1126/sciadv.aao5508 · Cited by 101
Self-citationCRISPR/Cas9 gene editing for curing sickle cell disease
Park, S. H., & Bao, G. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103060 · Cited by 118
Modeling Disease In Vivo With CRISPR/Cas9
Dow, L. E. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.07.006 · Cited by 111
Resources for the design of CRISPR gene editing experiments
Graham, D. B., & Root, D. E. (2015) · Genome biology · doi:10.1186/s13059-015-0823-x · Cited by 108
Friend or Foe? Evidence Indicates Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein
Chen, R., Huang, H., Liu, H., Xi, J., Ning, J., Zeng, W., Shen, C., Zhang, T., Yu, G., Xu, Q., et al. (2019) · Small · doi:10.1002/smll.201902686 · Cited by 109
CRISPR technologies for stem cell engineering and regenerative medicine
Hsu, M., Chang, Y., Truong, V. A., Lai, P., Nguyen, T. K. N., & Hu, Y. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107447 · Cited by 106
TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals
Manfredi, F., Cianciotti, B. C., Potenza, A., Tassi, E., Noviello, M., Biondi, A., Ciceri, F., Bonini, C., & Ruggiero, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01689 · Cited by 108
Eliminating base-editor-induced genome-wide and transcriptome-wide off-target mutations
Wang, L., Xue, W., Zhang, H., Gao, R., Qiu, H.-Y., Wei, J., Zhou, L., Lei, Y.-N., Wu, X., Li, X., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00671-4 · Cited by 106
Self-citationEnabling functional genomics with genome engineeringPreprint
Hilton, I. B., & Gersbach, C. A. (2015) · Genome Research · doi:10.1101/gr.190124.115 · Cited by 106
Structural basis for the altered PAM recognition by engineered CRISPR-Cpf1
Nishimasu, H., Yamano, T., Gao, L., Zhang, F., Ishitani, R., & Nureki, O. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.04.019 · Cited by 102
CRISPR/Cas9 for Human Genome Engineering and Disease Research
Xiong, X., Chen, M., Lim, W. A., Zhao, D., & Qi, L. S. (2016) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083115-022258 · Cited by 111
Decoding non-random mutational signatures at Cas9 targeted sites
Taheri‐Ghahfarokhi, A., Taylor, B., Nitsch, R., Lundin, A., Cavallo, A.-L., Madeyski-Bengtson, K., Karlsson, F. H., Clausen, M., Hicks, R., Mayr, L. M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky653 · Cited by 111
Carrier strategies boost the application of CRISPR/Cas system in gene therapy
Xu, Z., Wang, Q., Zhong, H., Jiang, Y., Shi, X., Yuan, B., Yu, N., Zhang, S., Yuan, X., Guo, S., et al. (2022) · Exploration · doi:10.1002/exp.20210081 · Cited by 105
Editing Citrus Genome via SaCas9/sgRNA System
Jia, H., Xu, J. H., Orbović, V., Zhang, Y., & Wang, N. (2017) · Frontiers in Plant Science · doi:10.3389/fpls.2017.02135 · Cited by 102
An overview and metanalysis of machine and deep learning-based CRISPR gRNA design tools
Wang, J., Zhang, X., Cheng, L., & Luo, Y. (2019) · RNA Biology · doi:10.1080/15476286.2019.1669406 · Cited by 106
Principles of Genetic Engineering
Lanigan, T. M., Kopera, H. C., & Saunders, T. L. (2020) · Genes · doi:10.3390/genes11030291 · Cited by 114
Role of GABA in the regulation of the central circadian clock of the suprachiasmatic nucleus
Ono, D., Honma, K., Yanagawa, Y., Yamanaka, A., & Honma, S. (2018) · The Journal of Physiological Sciences · doi:10.1007/s12576-018-0604-x · Cited by 107
Wang, Q., Alariqi, M., Wang, F., Li, B., Ding, X. L., Rui, H., Li, Y., Xu, Z., Qin, L., Sun, L., et al. (2020) · Plant Biotechnology Journal · doi:10.1111/pbi.13417 · Cited by 102
Rapidly inducible Cas9 and DSB-ddPCR to probe editing kinetics
Rose, J. C., Stephany, J. J., Valente, W. J., Trevillian, B. M., Dang, H. V., Bielas, J. H., Maly, D. J., & Fowler, D. M. (2017) · Nature Methods · doi:10.1038/nmeth.4368 · Cited by 101
Medeiros, L. C. S., South, L., Peng, D., Bustamante, J. M., Wang, W., Bunkofske, M. E., Perumal, N., Sánchez-Valdéz, F. J., & Tarleton, R. L. (2017) · mBio · doi:10.1128/mbio.01788-17 · Cited by 104
Gene therapy for visual loss: Opportunities and concerns
Lee, J. H., Wang, J.-H., Chen, J., Li, F., Edwards, T. L., Hewitt, A. W., & Liu, G. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.08.003 · Cited by 103
Synthetic Biology Tools for Novel Secondary Metabolite Discovery in Streptomyces
Lee, N., Hwang, S., Lee, Y., Cho, S., Palsson, B. Ø., & Cho, B. (2019) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1904.04015 · Cited by 102
Mashel, T. V., Tarakanchikova, Y. V., Muslimov, A. R., Zyuzin, M. V., Timin, A. S., Lepik, K. V., & Fehse, B. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120282 · Cited by 102
Suzuki, Y., Onuma, H., Sato, R., Sato, Y., Hashiba, A., Maeki, M., Tokeshi, M., Kayesh, M. E. H., Kohara, M., Tsukiyama–Kohara, K., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.013 · Cited by 102
Engineered CRISPR prime editors with compact, untethered reverse transcriptases
Grünewald, J., Miller, B. R., Szalay, R. N., Cabeceiras, P. K., Woodilla, C. J., Holtz, E. J. B., Petri, K., & Joung, J. K. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01473-1 · Cited by 103
Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9
Ren, J., & Zhao, Y. (2017) · Protein & Cell · doi:10.1007/s13238-017-0410-x · Cited by 103
m 6 A Regulates Liver Metabolic Disorders and Hepatogenous Diabetes
Li, Y., Zhang, Q., Cui, G., Zhao, F., Tian, X., Sun, B., Yang, Y., & Li, W. (2020) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2020.06.003 · Cited by 99
CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice
Stone, D., Long, K. R., Loprieno, M. A., Feelixge, H. S. D. S., Kenkel, E. J., Liley, R. M., Rapp, S., Roychoudhury, P., Nguyen, T., Stensland, L., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.014 · Cited by 98
Xiang, G., Li, Y., Sun, J., Huo, Y., Cao, S., Cao, Y., Guo, Y., Yang, L., Cai, Y., Zhang, Y. E., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01857-x · Cited by 106
Tremblay, F., Xiong, Q., Shah, S. S., Ko, C., Kelly, K., Morrison, M. S., Giancarlo, C., Ramírez, R. N., Hildebrand, E. M., Voytek, S. B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03508-x · Cited by 116
An RNA-aptamer-based two-color CRISPR labeling system
Wang, S. S., Su, J.-H., Zhang, F., & Zhuang, X. (2016) · Scientific Reports · doi:10.1038/srep26857 · Cited by 98
Self-citationEbrahimi‐Fakhari, D., Wahlster, L., Bartz, F., Werenbeck-Ueding, J., Praggastis, M., Zhang, J., Joggerst-Thomalla, B., Theiß, S., Grimm, D., Ory, D. S., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw204 · Cited by 99
Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease
Jarrett, K. E., Lee, C. M., Yeh, Y.-H., Hsu, R. H., Gupta, R., Zhang, M., Rodriguez, P. J., Lee, C. S., Gillard, B. K., Bissig, K., et al. (2017) · Scientific Reports · doi:10.1038/srep44624 · Cited by 100
Functional variomics and network perturbation: connecting genotype to phenotype in cancer
Yi, S. S., Lin, S., Li, Y., Zhao, W., Mills, G. B., & Sahni, N. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.8 · Cited by 105
Host determinants of adeno-associated viral vector entry
Pillay, S., & Carette, J. E. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.06.003 · Cited by 94
Glutamate Signaling in Hepatic Stellate Cells Drives Alcoholic Steatosis
Choi, W., Kim, H., Kim, M., Çınar, R., Yi, H., Eun, H. S., Kim, S., Choi, Y. J., Lee, Y., Kim, S. Y., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.001 · Cited by 98
Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9
Wu, J., Bell, O. H., Copland, D. A., Young, A., Pooley, J. R., Maswood, R. N., Evans, R. S., Khaw, P. T., Ali, R. R., Dick, A. D., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.012 · Cited by 100
Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b
Fatimy, R. E., Subramanian, S., Uhlmann, E. J., & Krichevsky, A. M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.004 · Cited by 102
New variants of CRISPR RNA‐guided genome editing enzymes
Murovec, J., Pirc, Ž., & Yang, B. (2017) · Plant Biotechnology Journal · doi:10.1111/pbi.12736 · Cited by 102
The Raphe Dopamine System Controls the Expression of Incentive Memory
Lin, R., Liang, J., Wang, R., Yan, T., Zhou, Y., Liu, Y., Feng, Q., Sun, F., Li, Y., Li, A., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.02.009 · Cited by 97
CRISPR/Cas System and Factors Affecting Its Precision and Efficiency
Javaid, N., & Choi, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.761709 · Cited by 106
The Cpf1 CRISPR-Cas protein expands genome-editing tools
Fagerlund, R. D., Staals, R. H. J., & Fineran, P. C. (2015) · Genome biology · doi:10.1186/s13059-015-0824-9 · Cited by 101
An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome
Harhouri, K., Frankel, D., Bartoli, C., Roll, P., Sandre‐Giovannoli, A. D., & Lévy, N. (2018) · Nucleus · doi:10.1080/19491034.2018.1460045 · Cited by 102
Lao, Y., Li, M., Gao, M. A., Shao, D., Chi, C., Huang, D., Chakraborty, S., Ho, T., Jiang, W., Wang, H., et al. (2018) · Advanced Science · doi:10.1002/advs.201700540 · Cited by 94
Dastidar, S., Ardui, S., Singh, K., Majumdar, D., Nair, N., Fu, Y., Reyon, D., Samara-Kuko, E., Gerli, M., Klein, A. F., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky548 · Cited by 104
Green Revolution to Gene Revolution: Technological Advances in Agriculture to Feed the World
Hamdan, M. F., Noor, S. N. M., Abd-Aziz, N., Pua, T., & Tan, B. C. (2022) · Plants · doi:10.3390/plants11101297 · Cited by 107
In Vivo Delivery Systems for Therapeutic Genome Editing
Wang, L., Li, F., Dang, L., Liang, C., Wang, C., He, B., Liu, J., Li, D., Wu, X., Xu, X., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050626 · Cited by 101
Self-citationCRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges
Yi, L., & Li, J. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.002 · Cited by 96
Yu, S., Yao, Y., Xiao, H., Li, J., Liu, Q., Yang, Y., Adah, D., Lu, J., Zhao, S., Li, Q., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.032 · Cited by 98
Effective PEI-mediated delivery of CRISPR-Cas9 complex for targeted gene therapy
Ryu, N., Kim, M.-A., Park, D., Lee, B., Kim, Y., Kim, K., Baek, J., Kim, W. J., Lee, K.-Y., & Kim, U. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.06.009 · Cited by 97
In Vivo Ryr 2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia
Pan, X., Philippen, L. E., Lahiri, S. K., Lee, C. M., Park, S. H., Word, T. A., Li, N., Jarrett, K. E., Gupta, R., Reynolds, J. O., et al. (2018) · Circulation Research · doi:10.1161/circresaha.118.313369 · Cited by 96
Genome editing opens a new era of genetic improvement in polyploid crops
Zaman, Q. U., Li, C., Cheng, H., & Hu, Q. (2018) · The Crop Journal · doi:10.1016/j.cj.2018.07.004 · Cited by 93
Tadić, V., Josipović, G., Zoldoš, V., & Vojta, A. (2019) · Methods · doi:10.1016/j.ymeth.2019.05.003 · Cited by 99
An endogenous opioid circuit determines state-dependent reward consumption
Castro, D. C., Oswell, C. S., Zhang, E. T., Pedersen, C. E., Piantadosi, S. C., Rossi, M. A., Hunker, A. C., Guglin, A., Morón, J. A., Zweifel, L. S., et al. (2021) · Nature · doi:10.1038/s41586-021-04013-0 · Cited by 95
Ahmadi, S. E., Soleymani, M., Shahriyary, F., Amirzargar, M. R., Mahya, O., Fattahi, D., & Safa, M. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00597-z · Cited by 97
Wu, Z., Cui, Y., Wang, H., Wu, H., Wan, Y., Li, B., Wang, L., Pan, S., Peng, W., Dong, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2212387120 · Cited by 95
Temperature effect on CRISPR-Cas9 mediated genome editing
Xiang, G., Zhang, X., An, C., Cheng, C., & Wang, H. (2017) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2017.03.004 · Cited by 93
Hit and go CAS9 delivered through a lentiviral based self-limiting circuit
Petris, G., Casini, A., Montagna, C., Lorenzin, F., Prandi, D., Romanel, A., Zasso, J., Conti, L., Demichelis, F., & Cereseto, A. (2017) · Nature Communications · doi:10.1038/ncomms15334 · Cited by 98
Off‐target effects of engineered nucleases
Yee, J. (2016) · FEBS Journal · doi:10.1111/febs.13760 · Cited by 95
Genome Editing in Clostridium saccharoperbutylacetonicum N1-4 with the CRISPR-Cas9 System
Wang, S., Dong, S., Wang, P., Tao, Y., & Wang, Y. (2017) · Applied and Environmental Microbiology · doi:10.1128/aem.00233-17 · Cited by 97
In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice
Nahmad, A. D., Lazzarotto, C. R., Zelikson, N., Kustin, T., Tenuta, M., Huang, D., Reuveni, I., Nataf, D., Raviv, Y., Horovitz‐Fried, M., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01328-9 · Cited by 93
Structures and mechanisms of CRISPR RNA-guided effector nucleases
Nishimasu, H., & Nureki, O. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.11.013 · Cited by 99
The Promise and Challenge of In Vivo Delivery for Genome Therapeutics
Wilson, R. C., & Gilbert, L. A. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00680 · Cited by 98
CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes
Ehrke‐Schulz, E., Schiwon, M., Leitner, T., Dávid, S., Bergmann, T., Liu, J., & Ehrhardt, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17180-w · Cited by 93
Lu, B., Javidi-Parsijani, P., Makani, V. S., Mehraein‐Ghomi, F., Sarhan, W. M., Sun, D., Yoo, K. W., Atala, Z., Lyu, P., & Atala, A. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz093 · Cited by 94
Homology-based double-strand break-induced genome engineering in plants
Steinert, J., Schiml, S., & Puchta, H. (2016) · Plant Cell Reports · doi:10.1007/s00299-016-1981-3 · Cited by 92
Rapid Molecular Profiling of Defined Cell Types Using Viral TRAP
Nectow, A. R., Moya, M. V., Ekstrand, M. I., Mousa, A., McGuire, K. L., Sferrazza, C. E., Field, B. C., Rabinowitz, G. S., Sawicka, K., Liang, Y., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.048 · Cited by 94
CRISPR/Cas systems: Delivery and application in gene therapy
Huang, J., Zhou, Y., Li, J., Lü, A., & Liang, C. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.942325 · Cited by 102
Discovery of Diverse CRISPR-Cas Systems and Expansion of the Genome Engineering Toolbox
Koonin, E. V., Gootenberg, J. S., & Abudayyeh, O. O. (2023) · Biochemistry · doi:10.1021/acs.biochem.3c00159 · Cited by 95
Self-citationTargeting miRNA by CRISPR/Cas in cancer: advantages and challenges
Hussen, B. M., Rasul, M. F., Abdullah, S. R., Hidayat, H. J., Faraj, G. S. H., Ali, F. A., Salihi, A. B., Baniahmad, A., Ghafouri‐Fard, S., Rahman, M., et al. (2023) · Military Medical Research · doi:10.1186/s40779-023-00468-6 · Cited by 106
Kemaladewi, D. U., Maino, E., Hyatt, E., Hou, H., Ding, M., Place, K. M., Zhu, X., Bassi, P. S., Baghestani, Z., Deshwar, A. G., et al. (2017) · Nature Medicine · doi:10.1038/nm.4367 · Cited by 96
Versatility of chemically synthesized guide RNAs for CRISPR-Cas9 genome editing
Kelley, M. L., Strezoska, Ž., He, K., Vermeulen, A., & Smith, A. V. B. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2016.06.011 · Cited by 89
In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model
Carreras, A., Pane, L. S., Nitsch, R., Madeyski-Bengtson, K., Porritt, M. J., Akçakaya, P., Taheri‐Ghahfarokhi, A., Ericson, E., Bjursell, M., Pérez-Alcázar, M., et al. (2019) · BMC Biology · doi:10.1186/s12915-018-0624-2 · Cited by 93
Metadata
- Authors
- Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., Koonin, E. V., Sharp, P. A., & Zhang, F.
- Affiliations
- Broad Institute (US)
- Massachusetts Institute of Technology (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- National Institutes of Health (US)
- Corresponding author
- Zhang, Feng
- ORCID
- Venue
- Nature
- Published
- 2015-04
- Volume
- 520
- Issue
- 7546
- Pages
- 186-191
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4393360
- OpenAlex
- W2070614858
- Cited by
- 2,687
- References
- 51
- Citations by year
- 2026: 126 · 2025: 167 · 2024: 180 · 2023: 199 · 2022: 285 · 2021: 263 · 2020: 274 · 2019: 261 · 2018: 264 · 2017: 288 · 2016: 264 · 2015: 113
- FWCI
- 134.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Institute of Mental Health (DP1MH100706)
- National Eye Institute (R01EY024259, P30EY012196)
- National Cancer Institute (R01CA133404, P01CA042063, P30CA014051, P30-CA-14051, P01 CA 42063)
- National Institute of General Medical Sciences (R01GM034277, T32GM008313, R01 GM34277, T32GM007753)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097768)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- SaCas9, SpCas9, CRISPR/Cas9, in vivo gene editing, adeno-associated virus delivery, PCSK9, cholesterol regulation, targeting specificity, single guide RNA
- MeSH terms
- Proprotein Convertase 9, Animals, Base Sequence, Cholesterol, Genetic Engineering, Liver, Male, Mice, Inbred C57BL, Serine Endopeptidases, Staphylococcus aureus, Substrate Specificity, Genome, Gene Targeting, Proprotein Convertases, Mice, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
